© 2020 MJH Life Sciences and Cancer Network. All rights reserved.
Myelodysplastic Syndromes
FDA Grants Breakthrough Therapy Designation for Pevonedistat to Treat Higher-Risk MDS
July 30, 2020
ByMatthew FowlerTakeda Pharmaceutical Company Limited announced the FDA granted pevonedistat, its investigation NEDD8-activating enzyme inhibitor, breakthrough therapy designation to treat patients with higher-risk myelodysplastic syndrome.
FDA Approves Oral Combo of Decitabine and Cedazuridine for Myelodysplastic Syndromes
July 07, 2020
ByHannah SlaterThe FDA has approved an oral combination of decitabine and cedazuridine for adult patients with myelodysplastic syndromes.
FDA Approves Luspatercept to Treat Anemia in Patients with Lower-Risk MDS
April 06, 2020
ByKristie L. KahlThe FDA approved the first and only erythroid maturation agent for the treatment of anemia in patients with lower-risk myelodysplastic syndromes.